Fate Therapeutics financials
$2.380.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M | $31.4M | $10.7M | $4.7M | $4.1M | $4.4M |
| Gross profit | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M | $31.4M | $10.7M | $4.7M | $4.1M | $4.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M | -$128.1M | -$100.7M | -$67.1M | -$42.1M | -$32.0M |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M | -$212.2M | -$173.4M | -$98.1M | -$66.6M | -$43.0M | -$33.5M |
| Net margin | −2051.1% | −1366.5% | −253.3% | −292.5% | −379.9% | −551.6% | −919.0% | −1405.0% | −1046.1% | −760.2% |
| Diluted EPS | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.44 | $-1.19 | $-1.02 | $-1.05 |
| EBITDA | -$134.8M | -$176.6M | -$165.0M | -$292.0M | -$207.1M | -$121.9M | -$97.9M | -$65.8M | -$41.2M | -$31.1M |
| Operating cash flow | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M | -$39.2M | -$83.2M | -$38.6M | -$36.8M | -$29.8M |
| Free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M | -$213.6M | -$44.2M | -$90.6M | -$41.0M | -$38.5M | -$30.3M |
| Diluted shares | 118.8M | 113.7M | 98.4M | 96.8M | 94.7M | 82.4M | 68.2M | 56.2M | 42.0M | 31.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.6M | $36.1M | $41.9M | $61.3M | $133.6M | $167.3M |
| Short-term investments | $157.0M | $243.0M | $273.3M | $374.9M | $482.3M | $315.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $4.0M | $4.0M |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M | $622.5M |
| Total liabilities | $111.5M | $121.4M | $137.8M | $221.6M | $242.6M | $238.0M |
| Shareholders' equity | $207.2M | $318.7M | $368.4M | $483.9M | $678.8M | $384.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology